The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...

NICE is also looking at the role of Hympavzi in treating severe haemophilia A, where there are other subcutaneous options ...

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and in most cases resolve within a few ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

Arguably, the step historically limiting growth of the radiotherapeutics sector is radioisotope generation. Isotopes are ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Sexual health services in the UK will start rolling out a 'world-first' vaccine programme designed to protect people from ...

The policy has been outlined in an editorial in the New England Journal of Medicine (NEJM) by FDA Commissioner Marty Makary ...

President Donald Trump's plan to introduce a most favoured nation (MFN) system of drug pricing controls is not quite what he ...

The drug – which is an intranasal formulation of 5-MeO-DMT benzoate, a psychoactive compound found in a wide variety of plant ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...